Corpus ID: 212513820

Tramadol: a wonder drug for the treatment of chronic pain?

  title={Tramadol: a wonder drug for the treatment of chronic pain?},
  author={A. Maslow},
Chronic pain is one of the most prevalent, costly and disabling conditions in both clinical practice and the workplace, yet often remains inadequately treated. Musculoskeletal conditions, such as low-back pain and osteoarthritis (OA), are the leading causes of disability among individuals of working age. The goals of adequate pain management include pain relief, minimizing disability, improving quality of life and preventing progression of the disease [1]. Optimal management requires a… Expand


The use of opioids in the treatment of osteoarthritis: When, why, and how?
Patient education and informed consent, exercise, complementary medicine, and the use of a controlled substance agreement increases the likelihood of patient compliance with treatment guidelines, improving functional capacity and quality of life. Expand
Chronic non-cancer pain: Focus on once-daily tramadol formulations
Three randomized controlled trials (RCTs) established OD tramadol analgesic efficacy to be superior to that of placebo for pain management and functional improvement in patients with osteoarthritis, and an open trial on long term tolerability showed that OD tramADol is generally safe in rheumatological pain treatment. Expand
Paracetamol/Tramadol association: the easy solution for mild-moderate pain.
The fixed association par acetamol/tramadol is a new therapeutic option, particularly useful in mild-moderate pain where paracetamol is inadequate, and a wide international literature exists for this association. Expand
Oral or transdermal opioids for osteoarthritis of the knee or hip.
The small to moderate beneficial effects of non-tramadol opioids are outweighed by large increases in the risk of adverse events and should therefore not be routinely used, even if osteoarthritic pain is severe. Expand
Medications for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline
Current evidence on benefits and harms of medications for acute and chronicLow back pain is reviewed as part of a larger evidence review commissioned by the American Pain Society and the American College of Physicians to guide recommendations for management of low back pain. Expand
The Management of Persistent Pain in Older Persons
This guideline was developed and written under the auspices of the American Geriatrics Society (AGS) Panel on Persistent Pain in Older Persons and approved by the AGS Board of Directors on April 8, 2002. Expand
Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
Odds ratios showed that the incidences of somnolence and dizziness were similar; however, nausea, vomiting, and constipation were significantly less likely with tapentadol IR compared with oxycodone IR, suggesting that drug tapering may not be necessary after tapentADol IR treatment of this duration. Expand
Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.
The combination of these reduced treatment discontinuation rates and tapentadol efficacy for the relief of moderate to severe nociceptive and neuropathic pain may offer an improvement in pain therapy by increasing patient compliance with their treatment regimen. Expand
An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
It is important that cardiologists, who are not among those physicians frequently prescribing NSAIDs, have a particular responsibility to have up-to-date, thoughtfully synthesized information about the CV risks of these drugs, especially when administered to patients receiving low-dose aspirin for cardioprotection. Expand
4 years after withdrawal of rofecoxib: where do we stand today?
It cannot be excluded that non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) may be associated with a small increase in the absolute risk for thrombotic events, and the entire substance group of NSAIDs may have cardiovascular side effects but to different degrees. Expand